Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the present invention relates to the application as a medicament of D-aspartic acid / -hydroxamate, abbreviated as DAH, of formula:
• DAH can be formed by the reaction of an activated acyl group of the D-isomer of aspartic acid or one of its derivatives, with the hydroxylamine following the reaction:
• DAH can also be prepared enzymatically from D-aspartic acid. It is a known product available on the market, for example product A 9009 from the company SIGMA in the 1987 catalog (French version).
• DAH is prepared by hydroxyamination of D-asparagine or
• H the three protons in position ⁇ and ⁇ of DAH constitute an ABX type system.
• the DAH mass spectrum was established on a VARIAN MAT CHS with an ionization energy of 70 eV.
• the molecular ion of DAH has a zero relative abundance, m / e (%): M + 148 (0); 97 (11); 97 (37); 54 (35); 44 (100);
• the hydroxamate function of DAH is demonstrated by an Fe3 + -hydroxamate complex which gives a red-violet coloration, quantified by colorimetric method at 550 nm, using a Beck an DU 70 spectrophotometer.
• the subject of the invention is the application of DAH as a medicament, in particular intended for the treatment of viral infections, more particularly those due to retroviruses, in particular those causing AIDS, and to the treatment of tumors.
• DAH has been shown to potentiate the anti-tumor activity of L-asparaginase. It is known that L-asparaginase is an anti-tumor agent. This activity being insufficient, we tried to strengthen it by combining L-asparaginase with other products. The association with DAH has not produced practically usable results. It has now surprisingly been found that DAH alone has antiretroviral activity, in particular against the viruses responsible for AIDS. It has also been found that DAH, administered at specific dosages, has an inhibitory action on tumors.
• antiviral agents can be broadly classified into three categories, the borders between them often being arbitrary: chemical agents, stimulators of the immune system and activators of l cell state antiviral.
• activators of the immune response are agents capable of activating non-specific defenses (macrophages, natural "killer” cells) or, more rarely, specific defenses (“B” or “T” lymphocytes). ") of the organization. For the most part, these agents are still in the experimental phase. Unlike chemical agents, the essential characteristics of their mode of action are their very broad spectrum of action and the fact that they cannot select resistant variants. However, they are for the moment limited in number and ineffective, although progress has recently been made in this direction (KOFF WC, SHOWALTER SD, HAMPAR B. and FIDLER IJ, Science, 128, 495-496, 1985) .
• Inducers of the antiviral cell state include interferon (IF), IFN inducers and IFN substitutes. It is a still very small group of substances which are characterized by arousing in the cells a state of resistance to viral infection. These agents combine the power of action at the cellular level with chemical agents and the very broad spectrum of action of activators of the immune system. Because they act on all cells, whether they have been infected or not, a determining factor in their effectiveness is their low toxic power towards the cells.
• IF interferon
• IFN inducers IFN substitutes. It is a still very small group of substances which are characterized by arousing in the cells a state of resistance to viral infection. These agents combine the power of action at the cellular level with chemical agents and the very broad spectrum of action of activators of the immune system. Because they act on all cells, whether they have been infected or not, a determining factor in their effectiveness is their low toxic power towards the cells.
• retroviruses represent a group responsible for particularly serious conditions that are difficult to combat.
• Retroviruses and their carcinogenic power are not a scientific novelty. At the beginning of the century, several researchers had identified, in animals, transmissible agents capable of causing leukemias and solid tumors (ROUS P., J. Am. Med. Assoc, 56, 198, 1911). In the following decades, retroviruses were found in many animal species. Prolonged efforts by researchers led to the isolation, in 1980, of the first human retrovirus: the lymphotropic virus of human T lymphocytes type I (HTLV-I) (POIESZ BJ et al, Proc. Natl Acad. Sci. USA, 21 r 7415, 1980). HTLV-I causes a rare and extremely malignant cancer, adult T-cell leukemia, which is endemic in parts of Japan, Africa and the Caribbean.
• the FLV virus is a type C murine retrovirus which produces rapid effects on erythropoiesis, the erythroid precursors being the target cells of this virus.
• the Friend complex includes a transforming virus that is defective in replication called SFFV (Spleen Focus Forming Virus) because it is capable of inducing macroscopic foci of transformed cells in the spleen of infected adult mice and a helper virus called the F-MuLV (Friend Murine Leukemia Virus) which is used for replication.
• SFFV Single Focus Forming Virus
• F-MuLV Friend Murine Leukemia Virus
• FL-V-induced erythroleukemia shows two stages: an early stage characterized by the rapid growth in the number of relatively mature erythropoietic precursors with limited proliferation capacity, and a late stage characterized by the emergence of precursors undifferentiated with an intense proliferation capacity.
• the manifestations of this disease are splenomegaly accompanied by hepatomegaly, erythroid hyperplasia in the spleen and bone marrow, polycytemia and macroscopic foci in the spleen.
• the last stages are characterized by the presence of immortal and transplantable erythroid cells.
• DAH causes a significant inhibition of the multiplication of viruses belonging to the family of retroviruses or of viruses whose replication is apparent therein, such as the so-called "hepadna viridae” viruses.
• This has been demonstrated in vitro with the AIDS virus (HIV) and .in . in vivo with FRIEND virus (FLV - Friend Leukemia Virus) which is a murine type C retrovirus.
• Retroviruses like any other virus, cannot reproduce without diverting the biosynthetic apparatus of the cell to their advantage.
• the special feature is their ability to reverse the usual flow of information.
• genetic tion In retroviruses, genetic material consists of RNA, which an enzyme, reverse transcriptase, uses to synthesize DNA; this viral DNA can integrate into the genome of the host cell.
• the present invention also relates to a new medicinal composition, intended in particular for the treatment of viral infections, in particular those linked to AIDS, as well as for the treatment of tumors, characterized by the fact that it contains, as a principle active, in a pharmaceutically acceptable carrier D- aspartic acid /.-monohydroxamate (DAH).
• D- aspartic acid /.-monohydroxamate D- aspartic acid /.-monohydroxamate
• the composition of the invention may also contain inert or pharmacodynamically active additives.
• the medicinal composition of the invention may be in the form of a lyophilized powder of the active substance to be dissolved extemporaneously in a physiological solution, for the purpose of injection.
• the medicament can then be administered parenterally, for example intravenously, intraperitoneally, in the cerebrospinal fluid, etc.
• the active ingredient is dissolved in a physiological solution until the desired concentration for administration is obtained.
• the drug composition according to the invention can also be in a form suitable for oral administration.
• suitable forms are tablets, capsules, dragees, powders and granules.
• the doses to be administered are variable according to the duration of the treatment, the frequency of taking, the host, the nature and the severity of the disease.
• the invention also relates to the use of D-aspartic acid / -monohydroxamate (DAH) to manufacture a drug composition for the treatment of viral infections and tumors.
• DAH D-aspartic acid / -monohydroxamate
• D-aspartic acid /.-monohydroxamate Another subject of the invention is a process for the preparation of D-aspartic acid /.-monohydroxamate (DAH) comprising the monoesterification of D-aspartic acid with a view to obtaining D-aspartic acid / J-ethyl ester and the hydroxylation of the latter which leads to DAH.
• DAH can also be prepared by hydroxyamination of D-asparagine.
• the invention relates to a process for the preparation of a pharmaceutical composition, characterized by the fact that D-aspartic acid / - monohy ⁇ droxamate (DAH) is prepared in the form of lyophilized powder, which is intended to be dissolved extemporaneously in a physiological solution for injection, or else the active substance is placed in a form suitable for administration by the oral route, with possibly one or more inert or pharmacodynamically active additives.
• DAH D-aspartic acid / - monohy ⁇ droxamate
• the FLV virus is a type C murine retrovirus which produces rapid effects on erythropoiesis, the erythroid precursors being the target cells of this virus.
• the Friend complex comprises a transforming virus defective for replication, called the SFFV (Spleen focus forming virus) because it is capable of inducing macroscopic foci of transformed cells in the spleen of the infected adult mouse, and of a helper virus called F-MuLV (Friend Murine Leukemia Virus) which is used for replication.
• SFFV Stpleen focus forming virus
• F-MuLV Friend Murine Leukemia Virus
• FL-V-induced erythro-leukemia shows two stages: an early stage characterized by the rapid growth in the number of relatively mature erythropoietic precursors with a limited proliferation capacity, and a late stage, characterized by the emergence of undifferentiated precursors with an intense proliferation capacity.
• the manifestations of this disease are splenomegaly accompanied by hepatomegaly, erythroid hyperplasia in the spleen and bone marrow, polycytemia and macroscopic foci in the spleen.
• the last stages are characterized by the presence of immortal and transplantable erythroid cells.
• the reverse transcriptase activity is lowered by about 70% by DAH to 0.2 mM, from 80% to 0.5 mM and from 90% to 1 mM.
• the anti-FLV effect observed does not result indirectly from a toxic effect of DAH on cell metabolism but from a direct effect on replication of the retrovirus.
• reverse transcriptase is the target of various anti-retroviral agents
• DAH reverse transcriptase
• the virus was maintained by successive intraperitoneal passages in the DBA / 2 mouse. This interview was done from the animal's spleen every 21 days. DAH activity was evaluated by comparing the survival times of animals to which the virus is injected, with or without DAH. The treatment started three days after the viral infection because it is considered that it takes this period of time for there to be sequences of the virus in the genome of the erythroid precursors of the infected mouse.
• Substance Dose (g / kg T / C days x 100 Active number of treatment weights (%) of body animals) (2) survivors
• T / C activity criterion equal to or greater than 125% is significant.
• DAH when administered in specific dosages, as defined below, has an inhibitory action on tumors.
• leukemia 1210 leukemia 1210
• RBL5 lymphoma melanoma
• L-aspartic acid ⁇ hydroxamate is very toxic.
• the increase in the doses of the abovementioned derivative D compared to the derivative L reveals an activity of the derivative D, without presenting the toxicity which the derivative L exhibits at the same dosages (the LD 50% for DAH is 10 g / kg while the LD 50% for LAH is 2.5 g / kg).
• mice The doses used for the treatment of mice varied from 0.5 g / kg to 1.5 g / kg for a minimum period of 3 days which can extend up to 10 days.
• L1210 leukemia cells are maintained by intraperitoneal passages in the male B6D2F1 / J mouse.
• the number of cells used for the therapeutic tests is 105 cells per mouse in 0.5 ml of PBS.
• the observation period is 30 days.
• Substance Dose (g / kg Days of T / CxlOO Number (3) Active evolution of treated weight ((%) of animals body weight) -ment (2) survivors (4)
• DAH The anti-tumor activity of DAH has also been studied in two other mouse models: L5178Y lymphoma and P388 leukemia.
• Murine lymphoma cells (L5178Y) are maintained by successive intraperitoneal passages in DBA / 2 mice and injected, for the tests, at a dose of 104 cells per mouse:
• the P388 leukemia cells are maintained by intraperitoneal passage in the DBA / 2 mouse and injected, for the tests, at a dose of 105 cells per mouse in the B6D2F1 mouse.
• SubstanceDose (g / kg Days of T / CxlOO Active number of treatment weights (%) of surviving body animals *
• SubstanceDose (g / kg Days of T / CxlOO Active number of treatment weights (%) of surviving body animals *
• DAH was assayed in the sera and urine of 8-week-old B6D2F1 mice given an intraperitoneal injection of DAH of 3 g / kg. DAH was assayed by spectrophotometry by highlighting the Fe3 + - hydroxa ate complex at 550 nm.
• the toxicity of parenteral DAH was evaluated in B6D2F1 mice six weeks old and weighing between 20 and 22 g. For each dose level, thirteen males and thirteen females were used with an observation period of 14 days. The lethal dose (LD) was evaluated 24 hours after the injection of DAH and then at 14 days. Under these conditions, it was possible to show that the LD 10 (10% mortality) was observed for dosages of 8.5-9 g / kg, the LD 50 corresponded to 11-12 g / kg and the LD 90 to 14 -15 g / kg. No significant difference in 24-hour and 14-day mortality was observed for a given dose level.
• the tolerance to the prolonged administration of DAH was evaluated on a group of 10 mice treated for 30 days with a daily injection of 2 g / kg, and a group of 10 mice receiving for the same duration two injections of 1 g / kg per day. Tolerance was excellent, with no clinical sign of toxicity, no death and a body weight remaining within +/- 10% compared to a control group of the same age and same initial weight.
• NCI National Cancer recommendations Institute
• Heart rate, electro-cardiogram, blood pressure (measured by intra-arterial catheterization), and respiratory rate were measured in dogs anesthetized with alphachloralosis. In animals having received an intravenous administration of DAH varying between 1 and 5 g / kg, no modification of these parameters was observed.
• Toxic effects of immediate appearance the intravenous injection of DAH at doses varying from 1 to 10 g / kg (in 10% solution) caused vomiting during the administration of the product. These vomiting disappeared at the end of the infusion and were accompanied by anorexia which could last up to 24 hours, depending on the size of the dose administered. No other symptoms of intolerance were observed during administration of DAH.
• Toxic effects of early onset hematological toxicity. A toxicity on the platelet line was noted from the dose of 5 g / kg, with a nadir of 39 x 109 platelets / 1 at the 8th day after the injection of DAH, and a return to the pre-treatment level seven to ten days later.
• DAH can be administered intravenously continuously to AIDS patients.
• the powdered DAH is put in physiological solution, for example at a concentration close to 10%.
• Each bottle contains 10 g of DAH for a single dose.
• DAH is then administered over 24 hours as a continuous infusion by peripheral venous route.
• the pre-clinical studies presented above provide an LD 10 value of 8.5 g / kg. Taking into account the correction factor mouse / human, the initial human dose would be 1.2 g / m body surface area z.
• administration may be carried out by continuous venous infusion over a period of 15 days, after the patients have received a unit dose equal to 1/24 of the daily dose, " in a one hour infusion, the eve of continuous infusion therapy.
• This protocol is similar to that used in the case of azidothy idine (Yarchoan et al., Lancet, 1986, 575-580). Increasing doses can be done as part of medical monitoring.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Virology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Epidemiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Molecular Biology (AREA)
• AIDS & HIV (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9381297

Family Applications (1)

Country Status (11)

Cited By (2)

Citations (1)

• 1989
  • 1989-04-28 FR FR8905744A patent/FR2646348A1/fr active Granted
• 1990
  • 1990-04-27 EP EP90907159A patent/EP0470144B1/fr not_active Expired - Lifetime
  • 1990-04-27 WO PCT/FR1990/000307 patent/WO1990013291A1/fr not_active Ceased
  • 1990-04-27 AU AU56575/90A patent/AU660916B2/en not_active Ceased
  • 1990-04-27 DK DK90907159.9T patent/DK0470144T3/da active
  • 1990-04-27 ES ES90907159T patent/ES2072431T3/es not_active Expired - Lifetime
  • 1990-04-27 JP JP2507392A patent/JPH04506796A/ja active Pending
  • 1990-04-27 DE DE69019148T patent/DE69019148T2/de not_active Expired - Fee Related
  • 1990-04-27 CA CA002050936A patent/CA2050936A1/fr not_active Abandoned
  • 1990-04-27 AT AT90907159T patent/ATE121935T1/de not_active IP Right Cessation
• 1991
  • 1991-10-25 OA OA60087A patent/OA09519A/fr unknown

Patent Citations (1)

Non-Patent Citations (13)

Also Published As

Similar Documents

Legal Events